ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
- Stock-based compensation, 2025
- $348M
- YoY, 2025
- +28.0%
- 5-year CAGR
- +20.0%
- 10-year CAGR
- +22.5%
Stock-based compensation
Stock-based compensation by fiscal year
| Period | Stock comp | YoY |
|---|---|---|
| 2025 | $348M | +28.0% |
| 2024 | $272M | +22.7% |
| 2023 | $222M | −3.9% |
| 2022 | $231M | +39.2% |
| 2021 | $166M | +18.5% |
| 2020 | $140M | −20.0% |
| 2019 | $175M | +10.8% |
| 2018 | $158M | +70.0% |
| 2017 | $93M | +22.9% |
| 2016 | $76M | +65.0% |
| 2015 | $46M | +38.5% |
| 2014 | $33M | +59.7% |
| 2013 | $21M | +67.5% |
| 2012 | $12M | −25.9% |
| 2011 | $17M | −12.8% |
| 2010 | $19M | −3.1% |
| 2009 | $20M | +9.4% |
| 2008 | $18M | — |